SlideShare a Scribd company logo
1 of 19
Steve Goldman, M.D.
ClinicalTrials.gov number, NCT00054847
A Randomized Trial Radial Artery
Graft vs. Saphenous Vein Grafts
           In CABG

                         Tucson VA
                          Hospital
I have no financial conflict of interest for
                this study.
   Arterial grafts - better conduits than veins – LIMA

   Other arterial grafts
       Right internal/free internal mammary, gastroepiploic,
        splenic
       Radial artery - easiest to harvest, most popular

   2008 - STS data base
       163,048 CABG
       10,319 radial artery grafts

   Problem - patency radial artery grafts not clear
   Prospective randomized trial
       One year angiographic patency Radial Artery (RA)
        vs Saphenous Vein (SV)
   11 VA medical centers (2003-2008)
       733 patients randomized
       RA – 366
       SV - 367
   Study graft either RA or SV
Albuquerque    Hines         New Orleans
Ann Arbor      Houston       Richmond
Birmingham     Little Rock   Tucson
West Roxbury   Minneapolis
    Radial artery better patency


    Proposed-one-year rates
       92%      RA
       83%      SV

    Goldman et al, 1988-1994   CSP’s 207/297/364, 2004
   90% power with a two-sided type I error of 5%
       Expected one-year catheterization completion
        rate of 65%


   Final enrollment
       733 patients, originally planned 874


   One-year catheterization completion rate (73%)
       Higher than expected
       Post hoc power 89% to detect 92% RA vs 83% SV
   Selective graft patency (RA vs SV)
     LAD: 83% vs 88%
     CX: 93% vs 89%
     RCA:   86% vs 88%

   No differences
   Disease in grafts
     More    high grade disease (string sign)
     RA   - 8% vs SV - 1%, (P<0.001)

   Endoscopic harvesting
     SV   - lower patency 78% vs 91%, (P=0.009)
      N = 72
     RA -   no difference 100% vs 89%
      N = 18
7.6%
  SYNTAX
Serruys et al.,
NEJM 360:961-972
     2009
   On pump vs off pump
       RA - no difference patency (89% vs 89%)
       SV - higher patency on pump (90% vs 78%)
       Off pump numbers small RA n=41 vs SV n=48


   Quality of life
       No difference at 3 months or 12 months
The other prospective randomized study RAPS
                   (Desai et.al NEJM 2004).


CSP-474                           RAPS


   Randomized RA or SV              Both RA and SV as
                                      study grafts
   Surgeon chose
    recipient vessel                 Randomized to
                                      recipient vessel
CSP-474                           RAPS
   One year patency no                  One year patency, RA
    difference                            better
       RA – 89% vs SV – 89%
                                          RA - 92% vs SV - 86%

   Best recipient vessel was
                                         Fewer patients
    study vessel                          required
                                         Cannot separate
   We can define:
                                          complications
       Patient characteristics
       Isolate complications
   One week cath/monitor
    disease progression
   No difference in radial artery graft vs
    saphenous vein graft at one year


   Our study group funded by VA Cooperative
    Studies Program for five year angiographic
    follow up
   Gulshan Sethi, M.D.,         Edward McFalls M.D.
   William Holman, M.D.
                                 Herb Ward, M.D.
                                 Rose Kelly, M.D.
   Kelvin Lee, Ph.D.
                                 Birger Rhenman, M.D.
   Stephen Fremes, M.D.         Gareth Tobler, M.D.
   Hoang Thai, M.D.             Faisal G. Bakaeen, M.D.
   Todd Wagner Ph.D.            Mohammed Moursi, M.D.
   Yajie Wang, M.S.             Michael Crittenden, M.D.
                                 Vigneshwar Kasirajan, M.D.
   Lori Planting, B.A.
                                 Claire Duvernoy, M.D.
   Meredith Miller, M.A.        Stewart Pett, M.D.
   Yvette Rodriguez, R.N.       Michelle Ratliff, M.D.
   Elizabeth Juneman, M.D.      Anand Irimpen, M.D.
   Douglas Morrison, M.D.       William Gunnar, M.D.
   Mary Kaye Pierce, N.P.
                                 Donald Thomas, M.D.
                                 Thomas Moritz, M.S.
   Sandra Kreamer R.N.
                                 Domenic Reda, Ph.D.
   Mei-Chiung Shih, Ph.D.       Lynn Harrison, M.D.
Radialv saphenous goldman

More Related Content

Viewers also liked

Viewers also liked (6)

Efecto de la flebectomía ambulatoria estética sin safenectomía en el diámetro...
Efecto de la flebectomía ambulatoria estética sin safenectomía en el diámetro...Efecto de la flebectomía ambulatoria estética sin safenectomía en el diámetro...
Efecto de la flebectomía ambulatoria estética sin safenectomía en el diámetro...
 
Insuficiencia Venosa
Insuficiencia VenosaInsuficiencia Venosa
Insuficiencia Venosa
 
AblacióN
AblacióNAblacióN
AblacióN
 
Saphenous Vein Harvesting
Saphenous Vein HarvestingSaphenous Vein Harvesting
Saphenous Vein Harvesting
 
Safenectomia
Safenectomia Safenectomia
Safenectomia
 
Insuficiencia Venosa de Miembros Inferiores
Insuficiencia Venosa de Miembros InferioresInsuficiencia Venosa de Miembros Inferiores
Insuficiencia Venosa de Miembros Inferiores
 

Similar to Radialv saphenous goldman

AMIM Février 2017 New diagnostic tools for GCA luqmani marrakesh
AMIM Février 2017 New diagnostic tools for GCA  luqmani marrakesh AMIM Février 2017 New diagnostic tools for GCA  luqmani marrakesh
AMIM Février 2017 New diagnostic tools for GCA luqmani marrakesh 020359
 
Carfilzomib In Newly Diagnosed Multiple Myeloma.pptx
Carfilzomib In Newly Diagnosed Multiple Myeloma.pptxCarfilzomib In Newly Diagnosed Multiple Myeloma.pptx
Carfilzomib In Newly Diagnosed Multiple Myeloma.pptxKunal Chhattani
 
IS STENTING TO MAINTAIN VASCULAR PATENCY GOING TO BE THE FUTURE
IS STENTING TO MAINTAIN VASCULAR PATENCY GOING TO BE THE FUTUREIS STENTING TO MAINTAIN VASCULAR PATENCY GOING TO BE THE FUTURE
IS STENTING TO MAINTAIN VASCULAR PATENCY GOING TO BE THE FUTUREAVATAR
 
Radiomics in Lung Cancer
Radiomics in Lung CancerRadiomics in Lung Cancer
Radiomics in Lung CancerWookjin Choi
 
Sequencing Agents in Metastatic Prostate Cancer
Sequencing Agents in Metastatic Prostate CancerSequencing Agents in Metastatic Prostate Cancer
Sequencing Agents in Metastatic Prostate Cancerflasco_org
 
Endeavor IV-A Randomized Comparison of a Zotarolimus-Eluting Stent Endeavor...
Endeavor IV-A Randomized Comparison of a Zotarolimus-Eluting Stent 	 Endeavor...Endeavor IV-A Randomized Comparison of a Zotarolimus-Eluting Stent 	 Endeavor...
Endeavor IV-A Randomized Comparison of a Zotarolimus-Eluting Stent Endeavor...MedicineAndFamily
 
2023-06 Vietnam SMA dissection.pdf
 2023-06 Vietnam SMA dissection.pdf 2023-06 Vietnam SMA dissection.pdf
2023-06 Vietnam SMA dissection.pdfssuser787e5c1
 
A_Rapid_Noninvasive_Assay_for_the_Detection_of 2013 96_17
A_Rapid_Noninvasive_Assay_for_the_Detection_of 2013 96_17A_Rapid_Noninvasive_Assay_for_the_Detection_of 2013 96_17
A_Rapid_Noninvasive_Assay_for_the_Detection_of 2013 96_17Kevin Jaglinski
 
TRIAL EVIDENCE OF TAVI
TRIAL EVIDENCE OF TAVITRIAL EVIDENCE OF TAVI
TRIAL EVIDENCE OF TAVIPraveen Nagula
 
The kSORT assay to detect renal transplant patients at risk for acute rejecti...
The kSORT assay to detect renal transplant patients at risk for acute rejecti...The kSORT assay to detect renal transplant patients at risk for acute rejecti...
The kSORT assay to detect renal transplant patients at risk for acute rejecti...Kevin Jaglinski
 
Australasian Laparoscopic Colon Cancer Study
Australasian Laparoscopic Colon Cancer StudyAustralasian Laparoscopic Colon Cancer Study
Australasian Laparoscopic Colon Cancer Studyensteve
 
The kSORT Assay to Detect Renal Transplant Patients at High Risk
The kSORT Assay to Detect Renal Transplant Patients at High RiskThe kSORT Assay to Detect Renal Transplant Patients at High Risk
The kSORT Assay to Detect Renal Transplant Patients at High RiskKevin Jaglinski
 
Interpretable Spiculation Quantification for Lung Cancer Screening
Interpretable Spiculation Quantification for Lung Cancer ScreeningInterpretable Spiculation Quantification for Lung Cancer Screening
Interpretable Spiculation Quantification for Lung Cancer ScreeningWookjin Choi
 
Clinical papers on TAVR
Clinical papers on TAVRClinical papers on TAVR
Clinical papers on TAVRSatya Shukla
 
Endobronchial Ultrasound Guidance of TBNA. Current Approach To Lung Cancer St...
Endobronchial Ultrasound Guidance of TBNA. Current Approach To Lung Cancer St...Endobronchial Ultrasound Guidance of TBNA. Current Approach To Lung Cancer St...
Endobronchial Ultrasound Guidance of TBNA. Current Approach To Lung Cancer St...Bassel Ericsoussi, MD
 
Surgical Treatment of Pancreatic Cancer - Dimitris P. Korkolis
Surgical Treatment of Pancreatic Cancer - Dimitris P. KorkolisSurgical Treatment of Pancreatic Cancer - Dimitris P. Korkolis
Surgical Treatment of Pancreatic Cancer - Dimitris P. KorkolisDimitris P. Korkolis
 
Coles alemtuzumab camm223 10yr efficacy safety aan 2016_poster p3.053
Coles alemtuzumab camm223 10yr efficacy safety aan 2016_poster p3.053Coles alemtuzumab camm223 10yr efficacy safety aan 2016_poster p3.053
Coles alemtuzumab camm223 10yr efficacy safety aan 2016_poster p3.053BartsMSBlog
 
The Big Picture for Mechanisms of Resistance in Prostate Cancer
The Big Picture for Mechanisms of Resistance in Prostate Cancer The Big Picture for Mechanisms of Resistance in Prostate Cancer
The Big Picture for Mechanisms of Resistance in Prostate Cancer GUMRC
 

Similar to Radialv saphenous goldman (20)

AMIM Février 2017 New diagnostic tools for GCA luqmani marrakesh
AMIM Février 2017 New diagnostic tools for GCA  luqmani marrakesh AMIM Février 2017 New diagnostic tools for GCA  luqmani marrakesh
AMIM Février 2017 New diagnostic tools for GCA luqmani marrakesh
 
Carfilzomib In Newly Diagnosed Multiple Myeloma.pptx
Carfilzomib In Newly Diagnosed Multiple Myeloma.pptxCarfilzomib In Newly Diagnosed Multiple Myeloma.pptx
Carfilzomib In Newly Diagnosed Multiple Myeloma.pptx
 
IS STENTING TO MAINTAIN VASCULAR PATENCY GOING TO BE THE FUTURE
IS STENTING TO MAINTAIN VASCULAR PATENCY GOING TO BE THE FUTUREIS STENTING TO MAINTAIN VASCULAR PATENCY GOING TO BE THE FUTURE
IS STENTING TO MAINTAIN VASCULAR PATENCY GOING TO BE THE FUTURE
 
Radiomics in Lung Cancer
Radiomics in Lung CancerRadiomics in Lung Cancer
Radiomics in Lung Cancer
 
Sequencing Agents in Metastatic Prostate Cancer
Sequencing Agents in Metastatic Prostate CancerSequencing Agents in Metastatic Prostate Cancer
Sequencing Agents in Metastatic Prostate Cancer
 
Endeavor IV-A Randomized Comparison of a Zotarolimus-Eluting Stent Endeavor...
Endeavor IV-A Randomized Comparison of a Zotarolimus-Eluting Stent 	 Endeavor...Endeavor IV-A Randomized Comparison of a Zotarolimus-Eluting Stent 	 Endeavor...
Endeavor IV-A Randomized Comparison of a Zotarolimus-Eluting Stent Endeavor...
 
2023-06 Vietnam SMA dissection.pdf
 2023-06 Vietnam SMA dissection.pdf 2023-06 Vietnam SMA dissection.pdf
2023-06 Vietnam SMA dissection.pdf
 
A_Rapid_Noninvasive_Assay_for_the_Detection_of 2013 96_17
A_Rapid_Noninvasive_Assay_for_the_Detection_of 2013 96_17A_Rapid_Noninvasive_Assay_for_the_Detection_of 2013 96_17
A_Rapid_Noninvasive_Assay_for_the_Detection_of 2013 96_17
 
TRIAL EVIDENCE OF TAVI
TRIAL EVIDENCE OF TAVITRIAL EVIDENCE OF TAVI
TRIAL EVIDENCE OF TAVI
 
Roberts J - AIMRADIAL 2015 - Ultrasound guidance
Roberts J - AIMRADIAL 2015 - Ultrasound guidanceRoberts J - AIMRADIAL 2015 - Ultrasound guidance
Roberts J - AIMRADIAL 2015 - Ultrasound guidance
 
The kSORT assay to detect renal transplant patients at risk for acute rejecti...
The kSORT assay to detect renal transplant patients at risk for acute rejecti...The kSORT assay to detect renal transplant patients at risk for acute rejecti...
The kSORT assay to detect renal transplant patients at risk for acute rejecti...
 
Australasian Laparoscopic Colon Cancer Study
Australasian Laparoscopic Colon Cancer StudyAustralasian Laparoscopic Colon Cancer Study
Australasian Laparoscopic Colon Cancer Study
 
The kSORT Assay to Detect Renal Transplant Patients at High Risk
The kSORT Assay to Detect Renal Transplant Patients at High RiskThe kSORT Assay to Detect Renal Transplant Patients at High Risk
The kSORT Assay to Detect Renal Transplant Patients at High Risk
 
Interpretable Spiculation Quantification for Lung Cancer Screening
Interpretable Spiculation Quantification for Lung Cancer ScreeningInterpretable Spiculation Quantification for Lung Cancer Screening
Interpretable Spiculation Quantification for Lung Cancer Screening
 
E-poster09 Iniguez aimradial20170921 Transradial bioresorbable stent
E-poster09 Iniguez aimradial20170921 Transradial bioresorbable stentE-poster09 Iniguez aimradial20170921 Transradial bioresorbable stent
E-poster09 Iniguez aimradial20170921 Transradial bioresorbable stent
 
Clinical papers on TAVR
Clinical papers on TAVRClinical papers on TAVR
Clinical papers on TAVR
 
Endobronchial Ultrasound Guidance of TBNA. Current Approach To Lung Cancer St...
Endobronchial Ultrasound Guidance of TBNA. Current Approach To Lung Cancer St...Endobronchial Ultrasound Guidance of TBNA. Current Approach To Lung Cancer St...
Endobronchial Ultrasound Guidance of TBNA. Current Approach To Lung Cancer St...
 
Surgical Treatment of Pancreatic Cancer - Dimitris P. Korkolis
Surgical Treatment of Pancreatic Cancer - Dimitris P. KorkolisSurgical Treatment of Pancreatic Cancer - Dimitris P. Korkolis
Surgical Treatment of Pancreatic Cancer - Dimitris P. Korkolis
 
Coles alemtuzumab camm223 10yr efficacy safety aan 2016_poster p3.053
Coles alemtuzumab camm223 10yr efficacy safety aan 2016_poster p3.053Coles alemtuzumab camm223 10yr efficacy safety aan 2016_poster p3.053
Coles alemtuzumab camm223 10yr efficacy safety aan 2016_poster p3.053
 
The Big Picture for Mechanisms of Resistance in Prostate Cancer
The Big Picture for Mechanisms of Resistance in Prostate Cancer The Big Picture for Mechanisms of Resistance in Prostate Cancer
The Big Picture for Mechanisms of Resistance in Prostate Cancer
 

More from Trimed Media Group

Top 5 Sessions to attend at HIMSS.15 (CVB)
Top 5 Sessions to attend at HIMSS.15 (CVB)Top 5 Sessions to attend at HIMSS.15 (CVB)
Top 5 Sessions to attend at HIMSS.15 (CVB)Trimed Media Group
 
Innovative technologies at ACC.15
Innovative technologies at ACC.15Innovative technologies at ACC.15
Innovative technologies at ACC.15Trimed Media Group
 
Imaging at ACC.15: Session Spotlight
Imaging at ACC.15: Session SpotlightImaging at ACC.15: Session Spotlight
Imaging at ACC.15: Session SpotlightTrimed Media Group
 
10 Sessions You Can’t Miss at ACC.15
10 Sessions You Can’t Miss at ACC.1510 Sessions You Can’t Miss at ACC.15
10 Sessions You Can’t Miss at ACC.15Trimed Media Group
 
6 simple tips to help you avoid a lawsuit
6 simple tips to help you avoid a lawsuit6 simple tips to help you avoid a lawsuit
6 simple tips to help you avoid a lawsuitTrimed Media Group
 
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf finalAos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf finalTrimed Media Group
 
Shorr and bria innovation at the point-of-care rethinking the doctor-patient...
Shorr and bria  innovation at the point-of-care rethinking the doctor-patient...Shorr and bria  innovation at the point-of-care rethinking the doctor-patient...
Shorr and bria innovation at the point-of-care rethinking the doctor-patient...Trimed Media Group
 
Kuperman Health Information Exchange & Care Coordination
Kuperman Health Information Exchange & Care CoordinationKuperman Health Information Exchange & Care Coordination
Kuperman Health Information Exchange & Care CoordinationTrimed Media Group
 
Safran info sage & disruptive innovation
Safran  info sage & disruptive innovationSafran  info sage & disruptive innovation
Safran info sage & disruptive innovationTrimed Media Group
 
[Hongsermeier] clinical decision support services amdis final
[Hongsermeier] clinical decision support services amdis final[Hongsermeier] clinical decision support services amdis final
[Hongsermeier] clinical decision support services amdis finalTrimed Media Group
 
Hamann big institution to community care
Hamann big institution to community careHamann big institution to community care
Hamann big institution to community careTrimed Media Group
 
Hongsermeier app store for health
Hongsermeier  app store for healthHongsermeier  app store for health
Hongsermeier app store for healthTrimed Media Group
 
Kibbe expect direct health information exchange in the context of state 2 mea...
Kibbe expect direct health information exchange in the context of state 2 mea...Kibbe expect direct health information exchange in the context of state 2 mea...
Kibbe expect direct health information exchange in the context of state 2 mea...Trimed Media Group
 
Crotty engaging patients in new ways from open notes to social media
Crotty  engaging patients in new ways from open notes to social mediaCrotty  engaging patients in new ways from open notes to social media
Crotty engaging patients in new ways from open notes to social mediaTrimed Media Group
 

More from Trimed Media Group (20)

HRS.15 Sessions to Attend
HRS.15 Sessions to AttendHRS.15 Sessions to Attend
HRS.15 Sessions to Attend
 
Himss cvb sessions
Himss cvb sessionsHimss cvb sessions
Himss cvb sessions
 
Top 5 Sessions to attend at HIMSS.15 (CVB)
Top 5 Sessions to attend at HIMSS.15 (CVB)Top 5 Sessions to attend at HIMSS.15 (CVB)
Top 5 Sessions to attend at HIMSS.15 (CVB)
 
Innovative technologies at ACC.15
Innovative technologies at ACC.15Innovative technologies at ACC.15
Innovative technologies at ACC.15
 
Imaging at ACC.15: Session Spotlight
Imaging at ACC.15: Session SpotlightImaging at ACC.15: Session Spotlight
Imaging at ACC.15: Session Spotlight
 
10 Sessions You Can’t Miss at ACC.15
10 Sessions You Can’t Miss at ACC.1510 Sessions You Can’t Miss at ACC.15
10 Sessions You Can’t Miss at ACC.15
 
6 simple tips to help you avoid a lawsuit
6 simple tips to help you avoid a lawsuit6 simple tips to help you avoid a lawsuit
6 simple tips to help you avoid a lawsuit
 
RSNA 2014
RSNA 2014RSNA 2014
RSNA 2014
 
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf finalAos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final
 
Acep 10-15-13
Acep 10-15-13Acep 10-15-13
Acep 10-15-13
 
Shorr and bria innovation at the point-of-care rethinking the doctor-patient...
Shorr and bria  innovation at the point-of-care rethinking the doctor-patient...Shorr and bria  innovation at the point-of-care rethinking the doctor-patient...
Shorr and bria innovation at the point-of-care rethinking the doctor-patient...
 
Kuperman Health Information Exchange & Care Coordination
Kuperman Health Information Exchange & Care CoordinationKuperman Health Information Exchange & Care Coordination
Kuperman Health Information Exchange & Care Coordination
 
Safran info sage & disruptive innovation
Safran  info sage & disruptive innovationSafran  info sage & disruptive innovation
Safran info sage & disruptive innovation
 
[Hongsermeier] clinical decision support services amdis final
[Hongsermeier] clinical decision support services amdis final[Hongsermeier] clinical decision support services amdis final
[Hongsermeier] clinical decision support services amdis final
 
[Teich] amdis
[Teich] amdis[Teich] amdis
[Teich] amdis
 
Hamann big institution to community care
Hamann big institution to community careHamann big institution to community care
Hamann big institution to community care
 
Hongsermeier app store for health
Hongsermeier  app store for healthHongsermeier  app store for health
Hongsermeier app store for health
 
Mandl app store for health
Mandl  app store for healthMandl  app store for health
Mandl app store for health
 
Kibbe expect direct health information exchange in the context of state 2 mea...
Kibbe expect direct health information exchange in the context of state 2 mea...Kibbe expect direct health information exchange in the context of state 2 mea...
Kibbe expect direct health information exchange in the context of state 2 mea...
 
Crotty engaging patients in new ways from open notes to social media
Crotty  engaging patients in new ways from open notes to social mediaCrotty  engaging patients in new ways from open notes to social media
Crotty engaging patients in new ways from open notes to social media
 

Radialv saphenous goldman

  • 2. A Randomized Trial Radial Artery Graft vs. Saphenous Vein Grafts In CABG Tucson VA Hospital
  • 3. I have no financial conflict of interest for this study.
  • 4. Arterial grafts - better conduits than veins – LIMA  Other arterial grafts  Right internal/free internal mammary, gastroepiploic, splenic  Radial artery - easiest to harvest, most popular  2008 - STS data base  163,048 CABG  10,319 radial artery grafts  Problem - patency radial artery grafts not clear
  • 5. Prospective randomized trial  One year angiographic patency Radial Artery (RA) vs Saphenous Vein (SV)  11 VA medical centers (2003-2008)  733 patients randomized  RA – 366  SV - 367  Study graft either RA or SV
  • 6. Albuquerque Hines New Orleans Ann Arbor Houston Richmond Birmingham Little Rock Tucson West Roxbury Minneapolis
  • 7. Radial artery better patency  Proposed-one-year rates  92% RA  83% SV Goldman et al, 1988-1994 CSP’s 207/297/364, 2004
  • 8. 90% power with a two-sided type I error of 5%  Expected one-year catheterization completion rate of 65%  Final enrollment  733 patients, originally planned 874  One-year catheterization completion rate (73%)  Higher than expected  Post hoc power 89% to detect 92% RA vs 83% SV
  • 9.
  • 10. Selective graft patency (RA vs SV)  LAD: 83% vs 88%  CX: 93% vs 89%  RCA: 86% vs 88%  No differences
  • 11. Disease in grafts  More high grade disease (string sign)  RA - 8% vs SV - 1%, (P<0.001)  Endoscopic harvesting  SV - lower patency 78% vs 91%, (P=0.009)  N = 72  RA - no difference 100% vs 89%  N = 18
  • 12. 7.6% SYNTAX Serruys et al., NEJM 360:961-972 2009
  • 13. On pump vs off pump  RA - no difference patency (89% vs 89%)  SV - higher patency on pump (90% vs 78%)  Off pump numbers small RA n=41 vs SV n=48  Quality of life  No difference at 3 months or 12 months
  • 14.
  • 15. The other prospective randomized study RAPS (Desai et.al NEJM 2004). CSP-474 RAPS  Randomized RA or SV  Both RA and SV as study grafts  Surgeon chose recipient vessel  Randomized to recipient vessel
  • 16. CSP-474 RAPS  One year patency no  One year patency, RA difference better  RA – 89% vs SV – 89%  RA - 92% vs SV - 86%  Best recipient vessel was  Fewer patients study vessel required  Cannot separate  We can define: complications  Patient characteristics  Isolate complications  One week cath/monitor disease progression
  • 17. No difference in radial artery graft vs saphenous vein graft at one year  Our study group funded by VA Cooperative Studies Program for five year angiographic follow up
  • 18. Gulshan Sethi, M.D.,  Edward McFalls M.D.  William Holman, M.D.  Herb Ward, M.D.  Rose Kelly, M.D.  Kelvin Lee, Ph.D.  Birger Rhenman, M.D.  Stephen Fremes, M.D.  Gareth Tobler, M.D.  Hoang Thai, M.D.  Faisal G. Bakaeen, M.D.  Todd Wagner Ph.D.  Mohammed Moursi, M.D.  Yajie Wang, M.S.  Michael Crittenden, M.D.  Vigneshwar Kasirajan, M.D.  Lori Planting, B.A.  Claire Duvernoy, M.D.  Meredith Miller, M.A.  Stewart Pett, M.D.  Yvette Rodriguez, R.N.  Michelle Ratliff, M.D.  Elizabeth Juneman, M.D.  Anand Irimpen, M.D.  Douglas Morrison, M.D.  William Gunnar, M.D.  Mary Kaye Pierce, N.P.  Donald Thomas, M.D.  Thomas Moritz, M.S.  Sandra Kreamer R.N.  Domenic Reda, Ph.D.  Mei-Chiung Shih, Ph.D.  Lynn Harrison, M.D.